Weight management built around labs, habits, and clinical eligibility

No. Tirzepatide and semaglutide pathways require intake, eligibility screening (including thyroid and pancreatic history), and licensed provider approval before any prescription is written.

ALUKARD is intake-first and lab-informed, and it routes members to coaching or foundational support when medication is not appropriate. Decline is an outcome - not a failure mode to hide.

Labs are not always required to begin coaching or foundational support, but basic metabolic, thyroid, lipid, and insulin-aware markers sharpen the recommendation and are often ordered before medication review.

Coaching focuses on protein intake, sleep architecture, training progression, and side-effect management when members are on GLP-1s. It's positioned as system design, not pep talks.

Members are guided through dose titration review, hydration and electrolyte context, protein timing, and medication interactions. Clinicians can pause or adjust the pathway at any point.

Long-term maintenance typically requires continued attention to protein intake, training, sleep, and habit structure. ALUKARD designs for sustainable adherence, not short-term weight drops.

Where legal in your state, compounded GLP-1 options may appear as part of a provider-reviewed pathway. ALUKARD is transparent that compounded formulations are not FDA-reviewed for efficacy, and availability shifts with regulatory updates.

Most providers want HbA1c, fasting glucose, fasting insulin, a comprehensive metabolic panel (kidney, liver), a lipid panel (ideally including ApoB), and thyroid labs. Pancreatic and gallbladder history are reviewed from intake rather than from a specific lab.

GLP-1s are contraindicated in personal or family history of medullary thyroid carcinoma or MEN2, active pancreatitis, pregnancy, and known hypersensitivity. Caution applies with gastroparesis, severe GERD, history of gallbladder disease, and certain eating-disorder histories. Final eligibility is a clinician decision at intake.

In the registrational trials, semaglutide 2.4 mg produced roughly 14-15% average weight loss over 68 weeks and tirzepatide 15 mg produced roughly 20-22% over 72 weeks, both alongside lifestyle support. Real-world results are typically lower and depend heavily on adherence, dose tolerance, and protein + training intake.

Most members see early appetite changes within 1-2 weeks, with meaningful scale change by weeks 6-12 during titration. Rate slows as dose stabilizes. ALUKARD's plan intentionally paces protein, hydration, and resistance training to protect lean mass - scale-only progress is not the target.

A common working target is roughly 1.2-1.6 g/kg of target body weight per day, distributed across 3-4 meals, to protect lean mass while appetite is suppressed. Actual targets are set at intake based on age, training load, and kidney function, and are adjusted by your coach.

Some lean-mass loss is expected with any weight loss, and GLP-1 trials show 25-40% of weight lost can be non-fat mass without countermeasures. Protein floors, resistance training, creatine, and adequate sleep materially reduce that share. This is a core focus of ALUKARD coaching on these pathways.

Published data (STEP 1 extension, SURMOUNT retrieval cohorts) show most members regain a substantial share of lost weight within 6-12 months of stopping without a structured maintenance plan. ALUKARD's protocol includes tapered dose strategy, re-labs, and coaching to hold the result.

New England Journal of Medicine - 2022

New England Journal of Medicine - 2021

American Diabetes Association - 2024